Integrating patient’s view of side-effects and genomics into a single risk report has tremendous potential.
The potential cost savings of OnPART™ & HSCT/Mucositis™ is a win-win for the patient, physician and payers.
With so many treatment possibilities in cancer, OnPART™ would have a very valuable role in making therapeutic equivalent treatment decisions.
The question isn’t why would we adopt these products, but rather why wouldn’t we?
Inform Genomics is uniquely positioned and qualified to develop and commercialize these products.